This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nicoll, A. J.
Right arrow Articles by Locarnini, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nicoll, A. J.
Right arrow Articles by Locarnini, S. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1998, p. 3130-3135, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Inhibition of Duck Hepatitis B Virus Replication by 9-(2-Phosphonylmethoxyethyl)adenine, an Acyclic Phosphonate Nucleoside Analogue

A. J. Nicoll,1 D. L. Colledge,1 J. J. Toole,2 P. W. Angus,3 R. A. Smallwood,3 and S. A. Locarnini1,*

Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria 3051,1 and Austin and Repatriation Medical Centre, Heidelberg, Victoria 3084,3 Australia, and Gilead Sciences, Foster City, California2

Received 9 February 1998/Returned for modification 28 May 1998/Accepted 29 August 1998

The use of regimens that use nucleoside analogues for the treatment of chronic hepatitis B virus infection is often limited because of their high relapse rates. This is thought to be due to the persistence of virus in nonhepatocyte reservoirs and/or the viral covalently closed circular (CCC) DNA species in the nucleus of infected hepatocytes. We have evaluated the novel nucleoside analogue 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in the duck model of hepatitis B. Eight Pekin-Aylesbury ducks congenitally infected with the duck hepatitis B virus (DHBV) were treated with PMEA at a dosage of 15 mg/kg of body weight/day via the intraperitoneal route for 4 weeks. At the end of the treatment period, four animals were killed and the remainder were monitored for a further 4-week drug-free period before analysis. The results were compared with those for eight age-matched, untreated controls. The levels of viremia, the total intrahepatic DHBV load, and CCC DNA, viral RNA, and protein levels were measured by Southern hybridization, Northern hybridization, and immunoblotting of the appropriate specimen, respectively. Viral proteins and DNA were also measured by immunohistochemistry (IHC) and in situ hybridization (ISH) of sections of liver and pancreatic tissue. PMEA treatment reduced the viremia to undetectable levels, while the total viral DNA load in the liver was reduced by 95% compared to the control level. Viral RNA and protein levels decreased by approximately 30%. ISH and IHC confirmed the PMEA-related intrahepatic changes and established that the amount of virus in bile duct epithelial cells (BDEC) was reduced by 70% during therapy. During the follow-up period all parameters of active virological replication returned to those for the age-matched controls. PMEA had no significant effect upon the number of virus-infected islet or acinar cells in the pancreas. PMEA at a dosage of 15 mg/kg/day has potent activity against DHBV found within hepatocytes and BDEC and inhibits DHBV replication in BDEC.

* Corresponding author. Mailing address: VIDRL, 10 Wreckyn St., North Melbourne, Victoria 3051, Australia. Phone: 61-3-9342 2614. Fax: 61-3-9342 2666. E-mail: stephenL{at}hna.ffh.vic.gov.au.

Antimicrobial Agents and Chemotherapy, December 1998, p. 3130-3135, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Delaney, W. E. IV, Yang, H., Miller, M. D., Gibbs, C. S., Xiong, S. (2004). Combinations of Adefovir with Nucleoside Analogs Produce Additive Antiviral Effects against Hepatitis B Virus In Vitro. Antimicrob. Agents Chemother. 48: 3702-3710 [Abstract] [Full Text]  
  • Foster, W. K., Miller, D. S., Marion, P. L., Colonno, R. J., Kotlarski, I., Jilbert, A. R. (2003). Entecavir Therapy Combined with DNA Vaccination for Persistent Duck Hepatitis B Virus Infection. Antimicrob. Agents Chemother. 47: 2624-2635 [Abstract] [Full Text]  
  • Karayiannis, P. (2003). Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother 51: 761-785 [Abstract] [Full Text]  
  • Abdelhamed, A. M., Kelley, C. M., Miller, T. G., Furman, P. A., Cable, E. E., Isom, H. C. (2003). Comparison of Anti-Hepatitis B Virus Activities of Lamivudine and Clevudine by a Quantitative Assay. Antimicrob. Agents Chemother. 47: 324-336 [Abstract] [Full Text]  
  • Delmas, J., Schorr, O., Jamard, C., Gibbs, C., Trepo, C., Hantz, O., Zoulim, F. (2002). Inhibitory Effect of Adefovir on Viral DNA Synthesis and Covalently Closed Circular DNA Formation in Duck Hepatitis B Virus-Infected Hepatocytes In Vivo and In Vitro. Antimicrob. Agents Chemother. 46: 425-433 [Abstract] [Full Text]  
  • Cullen, J. M., Li, D. H., Brown, C., Eisenberg, E. J., Cundy, K. C., Wolfe, J., Toole, J., Gibbs, C. (2001). Antiviral Efficacy and Pharmacokinetics of Oral Adefovir Dipivoxil in Chronically Woodchuck Hepatitis Virus-Infected Woodchucks. Antimicrob. Agents Chemother. 45: 2740-2745 [Abstract] [Full Text]  
  • Lee, J.-Y., Culvenor, J. G., Angus, P., Smallwood, R., Nicoll, A., Locarnini, S. (2001). Duck Hepatitis B Virus Replication in Primary Bile Duct Epithelial Cells. J. Virol. 75: 7651-7661 [Abstract] [Full Text]  
  • Delaney, W. E. IV, Edwards, R., Colledge, D., Shaw, T., Torresi, J., Miller, T. G., Isom, H. C., Bock, C. T., Manns, M. P., Trautwein, C., Locarnini, S. (2001). Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus. Antimicrob. Agents Chemother. 45: 1705-1713 [Abstract] [Full Text]  
  • Le Guerhier, F., Pichoud, C., Jamard, C., Guerret, S., Chevallier, M., Peyrol, S., Hantz, O., King, I., Trépo, C., Cheng, Y.-C., Zoulim, F. (2001). Antiviral Activity of {beta}-L-2',3'-Dideoxy-2',3'-Didehydro-5-Fluorocytidine in Woodchucks Chronically Infected with Woodchuck Hepatitis Virus. Antimicrob. Agents Chemother. 45: 1065-1077 [Abstract] [Full Text]  
  • de Vrueh, R. L. A., Rump, E. T., van de Bilt, E., van Veghel, R., Balzarini, J., Biessen, E. A. L., van Berkel, T. J. C., Bijsterbosch, M. K. (2000). Carrier-Mediated Delivery of 9-(2-Phosphonylmethoxyethyl)Adenine to Parenchymal Liver Cells: a Novel Therapeutic Approach for Hepatitis B. Antimicrob. Agents Chemother. 44: 477-483 [Abstract] [Full Text]  
  • Colledge, D., Civitico, G., Locarnini, S., Shaw, T. (2000). In Vitro Antihepadnaviral Activities of Combinations of Penciclovir, Lamivudine, and Adefovir. Antimicrob. Agents Chemother. 44: 551-560 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»